NCT04874948View on ClinicalTrials.gov

Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 8, 2021

Primary Completion Date

October 15, 2021

Study Completion Date

November 9, 2021

Conditions
TuberculosisTuberculosis, PulmonaryBacterial Infections RespiratoryLung DiseasesMycobacterium Infections
Interventions
DRUG

500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043

Single oral administration of 14C-labeled radioactive 500mg BTZ-043

Trial Locations (1)

Unknown

PRA Health Sciences (PRA) - Early Development Services (EDS), Groningen

All Listed Sponsors
collaborator

Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institute

OTHER

lead

Michael Hoelscher

OTHER

NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment | Biotech Hunter | Biotech Hunter